AzTrials
AzTrials

Premature BirthLONG LOVENCT05618769

Towards Life-Long Healthy Lungs: A Multidisciplinary Follow-up Framework for Preterm Infants

A study testing LONG LOVE Framework in people with Premature Birth and Respiratory Disease, run by Franciscus Gasthuis at 1 site in Netherlands.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Approximately 8% of all births occur between 30-36 weeks of gestation ('moderate-late' prematurity). Respiratory tract infections (RTI) and wheezing illnesses disproportionally affect preterm infants resulting in a 1.5-2 fold higher hospitalisation rate during the first years of life compared to term born children. Read more about this study

Who is it for?
Any age
What is being tested?
LONG LOVE Framework
Could I receive a placebo?
No, everyone receives an active treatment
How many people
330 participants
Where
1 siteNetherlands
Study dates
18 Jul 2022to 31 Jul 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Moderate-late preterm infants (GA 30+0 - 35+6 weeks)

Who cannot join

  • bronchopulmonary dysplasia (BPD)
  • congenital diaphragmatic hernia (CHD),
  • congenital pulmonary disorders
  • hemodynamic significant cardiac disease
  • immunodeficiency
  • severe failure to thrive;
  • birth asphyxia with poor neurological outcome
  • syndromic or other severe congenital disorders with decreased life expectancy

Trial locations and contacts

1 site in 1 country.

Kishan Tsang, MD contact

+31(0)683278272

k.tsang@franciscus.nl

Gerdien Tramper, MD, PhD contact

+31(10)4617126

g.tramper@franciscus.nl

Netherlands1 site, 1 recruiting
  • Franciscus Gasthuis & Vlietland

    Rotterdam, South Holland, 3045 PM

    Kishan Tsang, MD, +31(0)683278272, kishtsang@gmail.com

    Gerdien Tramper, MD, PhD, +31(0)104617126, g.tramper@franciscus.nl

    Recruiting

Other trials in Netherlands

About this study

Official title: Towards Life-Long Healthy Lungs: A Multidisciplinary Follow-up Framework for Preterm Infants (Dutch: Naar Levenslang Gezonde LONGen: Een multidiscipLinair zOrgpad Voor te Vroeg Geboren kindEren)

Approximately 8% of all births occur between 30-36 weeks of gestation ('moderate-late' prematurity). Respiratory tract infections (RTI) and wheezing illnesses disproportionally affect preterm infants resulting in a 1.5-2 fold higher hospitalisation rate during the first years of life compared to term born children. Besides prematurity, several other postnatal modifiable influencing factors are associated with increased risk of respiratory morbidity and impaired pulmonary development. These factors include RTI, rapid weight gain, air pollution, tobacco smoke exposition, vitamin D deficiency, maternal stress and antibiotic usage. The investigators hypothesize that a follow-up program aiming at prevention of modifiable influencing factors can reduce respiratory morbidity in moderate and late prematurity. Objectives: To reduce respiratory disease burden in moderate-late preterm infants in the first 18 months of life

Read the detailed description

Background of the study:

Approximately 8% of all births occur between 30-36 weeks of gestation (moderate-late prematurity). Respiratory tract infections (RTI) and wheezing illnesses disproportionally affect preterms, resulting in a 1.5-2 fold higher hospitalization rate during the first years of life compared to term-born children. Besides prematurity, several other modifiable influencing factors are associated with increased risk of respiratory morbidity and impaired pulmonary development. These factors include rapid weight gain and obesity at an early age, tobacco smoke exposure, air pollution, microbiome composition, and recurrent RTI.

To promote optimal lung health and development in moderate-late preterm infants, increased respiratory health surveillance and protection against RTI in early life might be crucial. Previous research has shown that the introduction of a multidisciplinary follow-up framework in children with bronchopulmonary dysplasia resulted in a significant reduction in hospital readmissions.

Despite the burden of respiratory disease, moderate to late preterms do not currently receive standardised respiratory follow-up care. With LONG LOVE, the investigators introduce a novel follow-up framework tailored for preterms and designed to improve respiratory health. As the risk of the onset of pulmonary disease is further increased by postnatal factors such as tobacco smoke exposure, air pollution and RTI, our main focus is the detection and treatment of these modifiable influencing factors. LONG LOVE incorporates eHealth and new technology in order to measure pulmonary function and air quality. Intervention strategies include counseling on nutrition, lifestyle, medication, and improving indoor air quality.

Objective of the study:

The project's overarching aim is to diminish respiratory disease burden in moderate-late preterm born infants in their first 18 months of life.

The investigators have formulated the following specific objectives:

  1. Determine whether the introduction of our follow-up framework will reduce the number and/or severity of RTI and wheezing episodes in the first 18 months of life
  2. Analyse the predictive value of nocturnal impedance pneumatography on lower respiratory symptoms in prematurely born infants < 1 year of age. Further, correlate this novel tool to other forms of pulmonary function analyses such as the Lung Clearance Index and Hypoxic Challenge Test.
  3. Conduct a cost-benefit analysis after the implementation of our framework.

Study design:

The investigators intend a quasi-experimental design based on a non-randomized cluster trial, in which moderate-late preterm-born infants will be allocated to the intervention or control group based on the location of birth. This design was chosen based on the limited amount of participating clusters and feasibility. As a quasi-experimental design can result in confounding by cluster and to increase internal validity, subjects of the control and intervention groups will be demographically matched at baseline[54,55]

Cluster 1 Consists of participants born in Franciscus Gasthuis (FG) and/or Vlietland (FV) and will be allocated to the intervention group, receiving additional (in addition to the current standard of care) follow-up in accordance with our newly developed framework to identify modifiable influencing factors compromising pulmonary health using validated questionnaires, weekly monitoring of respiratory symptoms as reported by parents using an app, in- and outdoor air quality measurements and non-invasive pulmonary function measurements based on impedance pneumatography.

In case of any modifiable influencing factors, appropriate lifestyle and/or medical interventions will be undertaken.

Cluster 2 (control) Consist of participants born in Maasstad Ziekenhuis (MSZ) and Albert Schweitzer Ziekenhuis (ASZ) and will receive standard of care follow-up.

Parents are requested to provide informed consent for the registration of outcome measurements and requested to complete validated questionnaires. Data on utilization of medical services will be inquired to avoid recall bias.

Study population:

Moderate-late preterm infants (GA 30+0-35+6 weeks) without other significant underlying syndromal, cardial, and/or pulmonal morbidities.

Intervention:

Follow-up regimen after premature birth using the LONG LOVE framework:

Identification of modifiable influencing factors Five study visits are scheduled to monitor health status on 1-1.5*, 3, 6, 12 and 18 months of age. These visits are planned in conjunction with regular follow-up examinations. Well-being and other potential risks will be determined by: growth, nutritional problems, feeding mode, pets, maternal stress (Edinburgh Postnatal Depression Scale questionnaire), sleep (Infant Sleep Questionnaire (ISQ)), tobacco smoke exposure, daycare attendance, the existence of siblings.

Air quality measurements Outdoor air analysis will be obtained using national and regional air measurement networks (RIVM Luchtmeetnet; DCMR Milieudienst Rijnmond). This network consists of a large number of air quality measurement sites, measuring harmful substances: nitric oxides (NOx, NO2), particulate matter (PM2.5, PM10), and ozone. Measurements will be taken from a station located nearest to the home address of the participant. Measurements are provided as publicly accessible data by the Dutch government.

Indoor air quality will be analyzed using a commercially available environment monitor. This device offers real-time monitoring of air quality factors such as temperature, humidity, particulate matter (PM1, PM2,5, PM10), carbon dioxide, and volatile organic compounds (VOCs). Air quality measurements will be taken from the living room or participants' sleeping room for a total duration of 1 year.

Pulmonary function analysis Pulmonary function analysis using impedance pneumatography will be measured at 3, 6, and 12 months of age during two consecutive nights using the Ventica recorder.

eHealth All parents are requested to install a newly developed application on their phones when enrolled in the study. The app is used for a weekly evaluation of respiratory symptoms. The following clinical parameters/variables will be monitored throughout the study: Respiratory health will be determined as follows: physician-diagnosed lower RTI- and wheezing episodes, hospitalizations for respiratory problems, clinical variables such as other respiratory episodes, common colds, medication use (bronchodilators, corticosteroids, antibiotics).

Interventions Aside from identification of potential health risks, our framework is designed to offer interventions if required. At baseline, all participants receive verbal and written information (App) defining potential hazardous factors regarding pulmonary development and overall health. In the event of pulmonary symptoms, parents are requested to consult a doctor.

In case of modifiable influencing factors, the following lifestyle and medical interventions will be performed:

In the case of 1.5 SDS weight gain or loss (based on birth weight), nutritional advice is provided by a paediatrician and follow-up by primary infant health care services.

In case of EPDS-scores ≥12 (stress-depression mother) consultation by lifestyle coach or community worker (Kleine Heldenhuis). If required, referral to general practitioner or psychologist/psychiatrist.

If sleep quality is affected (ISQ >12): medical advice and sleep training is provided by a paediatrician and/or primary infant health care services In the case of pulmonary symptoms: clinical assessment by a general practitioner or paediatrician. Administration of antibiotics according to Dutch board of Paediatricians guideline, optionally C-reactive protein measurement to prevent unnecessary antibiotics use If one or both caretakers are smoking: consultation by a general practitioner and primary infant health care services to provide stop-smoking services In case of inferior indoor air quality: visit by PhD-student or pulmonary care nurse to instruct how to improve air quality Optimal identification and treatment of comorbidity: gastro-oesophageal re ux disease, vitamin D deficiency, iron deficiency anaemia by paediatrician Active consultancy and treatment of nasal congestion using saline and-or xylometazoline by paediatrician Bronchodilator/broncholytic (salbutamol) trial by pediatrician in event of recurrent clinical bronchial obstruction and/or abnormal expiratory variability index using impedance pneumatography. If bronchodilator therapy is regularly required (a minimum of 2 episodes 2-3 days of week for a minimal duration of two weeks), inhaled corticosteroids can be prescribed.

These interventions are performed by both primary and secondary healthcare professionals (including the PhD-student who has an active role in patient management). Primary infant healthcare services operating in the Rijnmond region will fulfill an important role and are directly involved with the implementation of this framework.

Being tested
LONG LOVE Framework
Keywords
Moderate preterm, Late preterm, Post-Prematurity Respiratory Disease, Prematurity Associated Lung Disease, eHealth, mHeath, Follow-up, Respiratory Disease, Air pollution, Value Based Health Care
Medical subject headings
Premature Birth, Respiration Disorders, Respiratory Tract Infections, Bronchopulmonary Dysplasia, Smoking Cessation, Health Behavior, Respiratory Syncytial Virus Infections, Bronchial Hyperreactivity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • LONG LOVE FrameworkCombination product

    In order to identify modifiable influencing factors, clinical data of the infants included in our multidisciplinary framework will be continuously collected by eHealth (Luscii Healthtech BV, Netherlands). Study visits take place at 1-1,5 3, 6, 12 and 18 months of age. Outdoor air quality measurements will be conducted using RIVM Luchtmeetnet. Indoor air quality measurements will be collected during a period of 6 weeks using a commercial available device. Lung function analysis using impedance pneumatography (Ventica Recorder, Revenio Research LTD, Finland) will take place during 2 nights at 3, 6 and 12 months of age. In the event of modifiable influencing factors medical or lifestyle interventions will be undertaken.

Study groups in NCT05618769
Study groupRoleWhat they receive
Intervention (LONG LOVE Framework)ExperimentalConsists of participants born in Franciscus Gasthuis (FG) and/or Vlietland (FV) and will be allocated to the intervention group, receiving additional (in addition to current standard of care) follow-up in accordance with our newly developed framework to identify modi able influencing factors compromising pulmonary health using validated questionnaires, weekly monitoring of respiratory symptoms as reported by parents using an app, in- and outdoor air quality measurements and non-invasive pulmonary function measurements based on impedance pneumatography. In case of any modi able influencing factors, appropriate lifestyle and/or medical interventions will be undertaken.
Receives: Combination Product: LONG LOVE Framework
ControlNo interventionConsist of participants born in Maasstad Ziekenhuis (MSZ) and Albert Schweitzer Ziekenhuis (ASZ) and will receive standard of care follow-up. Parents are requested to provide informed consent for the registration of outcome measurements and requested to complete validated questionnaires. Data on utilization of medical services will be inquired to avoid recall bias.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of lower Respiratory Tract Infections (RTI)

    Total number of physician diagnosed lower RTI

    Measured: 18 months of life

  2. Number of wheezing episodes

    Total number of physician diagnosed wheezing episodes

    Measured: 18 months of life

Secondary outcomes (15)
  1. time to first lower RTI or wheezing episode

    Elapsed time from birth until first RTI

    Measured: 18 months of life

  2. total number of RTI

    Total number of RTI

    Measured: 18 months of life

  3. total number of wheezing episodes

    total number of wheezing episodes

    Measured: 18 months of life

  4. distribution of viruses (in case of hospital admission)

    PCR measured viral distribution in case of hospital admission

    Measured: 18 months of life

  5. medication use

    Number of prescriptions (bronchodilators, corticosteroids, antibiotics)

    Measured: 18 months of life

  6. lung function as measured by expiratory variability index (EVI)

    Average EVI in preterm infants

    Measured: 3, 6, 12 months of age

  7. comparison of expiratory variability index in moderate/late prematurity compared to term cohort (reference cohort from other center)

    Average EVI

    Measured: 3, 6, 12 months of age

  8. correlation between expiratory variability index and Lung Capacity Index and Hypoxic Challenge Test

    EVI correlation with LCI and HCT

    Measured: 6 months of age

  9. association between expiratory variability index and number of RTI/wheezing

    association between low expiratory variability index and number of RTI/wheezing-rate

    Measured: 18 months of life

  10. Analysis of outdoor air quality

    Analysis of outdoor air quality using sensor and satellite data for increased spatial resolution: exceedance of health-based criteria (WHO, EU); outdoor-indoor pollution relationship; and association between air pollution and respiratory complaints/hospital admissions

    Measured: 12 months

  11. indoor air quality

    Analysis of indoor air quality using low-cost air quality sensors: exceedance of health-based criteria (WHO, EU), outdoor-indoor pollution relations; effect of direct feedback and strategies on optimization of indoor air quality

    Measured: 12 months

  12. Preschool Children Quality of Life

    by TNO-AZL Preschool Children Quality of Life (TAPQOL)

    Measured: 12 and 18 months of life

  13. Total costs of framework

    Total costs of framework consist of healthcare costs (medication and other healthcare costs), productivity costs and patient costs. Healthcare use will be assessed with the institute of Medical Technology Assessment (iMTA) Medical Consumption Questionnaire (iMCQ)supplemented with information on respiratory-related medication use, outpatient clinic visits and diagnostics extracted from the medical chart. Patient costs consisted of informal care and were measured using the iMTA MCQ. Healthcare and patient costs were valued according to the Dutch guideline. Productivity losses were estimated with the iMTA Productivity Cost Questionnaire (iPCQ)24 every 12 weeks. Productivity loss consists of absenteeism (sick leave), presenteeism (reduced effectiveness at work) and loss of unpaid work and will be evaluated using the iPCQ questionnaire

    Measured: 18 months of life

  14. Care-related Quality of Life

    Measuring and valuating the impact of providing informal care on caregivers using the CarerQoL questionnaire

    Measured: 18 months of life

  15. Cost-effectiveness of framework

    Societal costs as specified under 15 will be compared between both intervention and control groups.

    Measured: 18 months of life

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Nov 2022
  2. Study start18 Jul 2022
  3. Primary completion30 Jun 2025 (estimated)
  4. Study completion31 Jul 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Non-randomised
Intervention model
Parallel groups
Model description
Quasi-experimental design based on a non-randomized cluster trial, in which moderate-late preterm born infants will be allocated to the intervention or control group based on location of neonatal care. This design was chosen based on the limited amount of participating clusters and feasibility. As a quasi-experimental design can result in confounding by cluster and to increase internal validity, subjects of the control and intervention groups will be demographically matched at baseline
Masking
None (open label)
Enrolment
330 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05618769
Sponsor's protocol ID
2021-117
Acronym
LONG LOVE
Status last verified
Sep 2022
First submitted
3 Oct 2022
Last updated
16 Nov 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing LONG LOVE Framework in people with Premature Birth and Respiratory Disease, run by Franciscus Gasthuis at 1 site in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 16 Nov 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Kishan Tsang, MD (+31(0)683278272, k.tsang@franciscus.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of lower Respiratory Tract Infections (RTI) (time frame: 18 months of life). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Nov 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in